复方仙酥胶囊联合化疗治疗中晚期胃癌的临床研究

目的：探讨复方仙酥胶囊配合化疗治疗中晚期胃癌的疗效及机理。方法：以复方仙酥胶囊配合化疗治疗６１例中晚期胃癌患者，并与单纯化疗３０例作对照，观察两组有效率、细胞免疫功能等。结果：对带瘤患者治疗组有效率为３２８％，对照组为１３３％（Ｐ＜００５），而毒副反应发生率治疗组低于对照组（Ｐ＜００１）。治疗组患者ＣＤ８下降，ＣＤ４／ＣＤ８升高，说明复方仙酥胶囊对Ｔ细胞免疫功能有调节作用。结论：复方仙酥胶囊对化疗有增效减毒作用，其调节细胞免疫功能可能是取得疗效机理之一。     

益龙血脉通胶囊对麻醉猫血液动力学的影响

目的：观察益龙血脉通胶囊对血液动力学的影响。方法：用多道生理记录仪和电磁流量记录麻醉状态下猫的各项血液动力学指标。结果：益龙血脉通胶囊可使心室压力、左心室压力最大变化速率、心输出量、心脏指数、脑血流量等明显增加,对平均动脉压、外周血管阻力没有明显影响。结论：益龙血脉通胶囊可使心脏缩力和心脏泵血功能增强,从而使心输出量增加;它对外周血管的扩张作用较弱,但可使脑血管阻力下降,脑血流量明显增加。     

“痛风康胶囊”治疗痛风病40例疗效观察

痛风病患者服用课题组研制的“痛风康胶囊”前后检测血尿酸值,统计得出该药降低血尿酸的总有效率为92．5％。经统计学处理,男女性别之间疗效差异无显著性（P＞0．05）。患者自身服药前后血尿酸值对照,差异有高度显著性（P＜0．01）,说明“痛风康胶囊”对降低血尿酸有很好的作用,可用于清风病的防治。     

痛风宁胶囊对小鼠高尿酸血症和肾脏功能的改善作用

目的：探讨痛风宁胶囊（TFN）对高尿酸血症模型小鼠血清中尿酸（UC）、肌酐（Cr）和尿素氮（BUN）水平以及小鼠肝脏匀浆液中黄嘌呤氧化酶（XOD）和腺苷脱氨酶（ADA）活性的影响,观察TFN对高尿酸小鼠肾脏组织病理学变化的改善作用,阐明其作用机制。方法：采用酵母膏合并氧嗪酸钾盐诱导建立小鼠高尿酸血症模型。将70只小鼠分为空白对照组,模型组,低（200 mg·kg^-1）、中（400 mg·kg^-1）和高剂量（800 mg·kg^-1） TFN组,别嘌醇（50 mg·kg^-1）和痛风舒（TFS,600 mg·kg^-1）阳性药对照组,每组10只,灌胃给药。实验结束后检测小鼠血清中UC、Cr和BUN水平以及小鼠肝脏匀浆液中XOD和ADA活性,HE染色观察小鼠肾脏组织病理表现。结果：与空白对照组比较,模型组小鼠血清中UC、Cr和BUN水平明显升高（P < 0.01）,肝组织中XOD和ADA活性亦升高（P < 0.01）;与模型组比较,阳性药对照组,低、中和高剂量TFN组小鼠血清中UC、Cr和BUN水平明显降低（P < 0.01）,肝组织中XOD和ADA活性降低（P < 0.05或P < 0.01）,其中高剂量TFN组效果最为明显。光镜下观察,与模型组比较,阳性药对照组和高剂量TFN组小鼠肾脏肾小球萎缩、肾间质纤维化和肾小管扩张等病理变化得到一定程度上改善。结论：TFN对小鼠高尿酸血症具有一定的改善作用,其机制与抑制UC生成和促进UC排泄有关。     

Babaodan Capsule (八宝丹胶囊) Combined with Qingyi Huaji Formula (清胰化积方) in Advanced Pancreatic Cancer—A Feasibility Study

Objective: To observe the clinical effects of Babaodan Capsule(八宝丹, BBD) combined with Qingyi Huaji Formula(清胰化积方, QYHJ) in treating patients with advanced pancreatic cancer. Methods: Eighty-one patients with advanced pancreatic cancer(from January 1, 2013 to December 31, 2014) were enrolled. Patients were assigned to two groups: QYHJ plus BBD group(40 cases) and QYHJ only group(41 cases), and there were no significant differences for other treatment between two groups. The survival and cancer-related symptoms were compared between two groups over two cycles of treatment. Results: The cancer-related symptoms of patients such as ascites, jaundice, pain, abdominal distension, anorexia and Karnofsky performance status of QYHJ plus BBD group were significantly improved as compared with those of the QYHJ group(P0.01). In addition, the 1-year survival rate of patients in QYHJ plus BBD group was longer than that in the QYHJ group(65% vs. 33%, respectively, P=0.0023). Conclusions: BBD with QYHJ is feasible treatment to prolong the survival of patients with advanced pancreatic cancer. However, it deserves to be further investigated in randomized clinical trials.     

化疗联合养正消积胶囊治疗中晚期大肠癌临床研究

目的:观察化疗联合养正消积胶囊治疗中晚期大肠癌的临床疗效。方法:将78例中晚期大肠癌患者随机分为观察组和对照组,对照组患者采用化疗治疗,观察组在化疗方案基础上加用养正消积胶囊口服,两组均治疗2个月。比较两组患者治疗后生存质量评分、临床疗效及临床症状改善情况。结果:观察组治疗后生存质量评分为(74.32±12.31)分,明显高于对照组的(67.24±11.98)分,两组比较,差异有统计学意义(P0.05);观察组治疗后有效率为89.74%,对照组有效率为61.54%,两组比较,差异有统计学意义(P0.01);观察组恶心、呕吐、食欲减退症状改善情况优于对照组,差异有统计学意义(P0.01);观察组不良反应明显低于对照组,差异有统计学意义(P0.01)。结论:化疗联合养正消积胶囊治疗中晚期大肠癌可明显提高患者生存质量,改善临床症状,减轻不良反应。     

正交设计结合药效学实验优选桂栀助眠胶囊提取工艺研究

目的优选桂栀助眠胶囊最佳提取工艺。方法在单因素实验结果基础上,采取正交试验法,以干膏得率和栀子苷转移率为指标,考察加水量、提取时间、提取次数3个因素,优选桂栀助眠胶囊最佳水提工艺;以药液浓度、药液含醇量、醇沉时间为考察因素,优选桂栀助眠胶囊最佳醇沉工艺;通过改善睡眠药效学实验对醇沉前后提取物进行比较。结果桂栀助眠胶囊最佳水提工艺为加10倍量水煎煮3次,每次0.5 h;最佳醇沉工艺为水提滤液浓缩至1 mL药液相当于原药材1 g,药液含醇量为80%,醇沉时间为12 h。与阴性对照组比较,桂栀助眠胶囊水提取物能延长戊巴比妥钠小鼠睡眠时间(P0.01),且能增加戊巴比妥钠阈下剂量小鼠入睡率(P0.05);水提醇沉物有延长巴比妥钠小鼠睡眠时间,增加小鼠入睡率的趋势,但差异无显著性(P0.05)。结论醇沉前后提取物药效存在差异,为不影响药效,最终选择水提工艺作为制剂的最佳提取工艺。     

杜仲补天素胶囊改善环磷酰胺诱导的小鼠生精障碍研究

目的采用环磷酰胺(cyclophosphamide,CP)诱导的小鼠生精障碍模型,探究杜仲补天素胶囊(Duzhong Butiansu Capsule,DBC)的生殖保护作用及其机制。方法采用昆明种小鼠ipCP(60mg/kg)制备生精障碍模型,连续5d,第8天起ig给予DBC高、低剂量(1.388、0.694 g/kg)干预4周,给药结束后检测各组小鼠体质量、脏器指数变化,HE染色检测睾丸病理结构变化,ELISA法测定血清睾酮(T)、促卵泡激素(FSH)、促黄体生成素(LH)、丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平;Western blotting及免疫组化法分析睾丸组织中转录因子NF-E2相关因子2(Nrf2)、血红素氧合酶-1(HO-1)、醌氧化还原酶1(NQO1)、组蛋白脱乙酰基酶2(HDAC2)与磷酸化蛋白激酶C(p-PKC)表达。结果与模型组比较,DBC对小鼠体质量下降有极显著干预作用,能够增加睾丸、附睾及肾脏指数,改善睾丸病理形态损伤,增加精子数、提高精子活力、降低精子畸形率,提高T水平,降低LH、FSH水平,降低MDA含量,提高SOD、GSH-Px活性,提高Nrf2、HO-1、NQO1、HDAC2与p-PKC蛋白的表达水平(P0.05、0.01)。结论 DBC能够改善CP诱导的小鼠生精障碍,其机制可能与调节氧化应激相关的Nrf2/抗氧化作用元件(ARE)信号通路有关。     

通络生骨胶囊治疗股骨头坏死(筋脉瘀滞证)的多中心随机、双盲、双模拟、阳性药对照临床研究

目的观察通络生骨胶囊治疗股骨头坏死(筋脉瘀滞证)的有效性及安全性。方法采用多中心随机、双盲、双模拟、阳性药对照临床研究设计,将600例股骨头坏死患者按照2∶1的比例随机分为试验组及对照组。对照组予口服通络生骨胶囊模拟剂、健骨生丸治疗,试验组予口服通络生骨胶囊、健骨生丸模拟剂治疗。两组疗程均为12周,比较两组不同观察时间点(治疗前、治疗4周、治疗8周、治疗12周、停药后4周)的髋关节Harris评分、中医证候积分、股骨头坏死ARCO分期的变化情况,同时评价安全性。结果①治疗4周、治疗8周、治疗12周和停药后4周,两组Harris评分较本组治疗前基线变化率差异有统计学意义(P0.05)。治疗12周、停药后4周组间比较,试验组Harris评分高于对照组(P0.05);治疗8周、治疗12周、停药后4周组间比较,Harris评分较基线变化率差异有统计学意义(P0.05)。②治疗4周、治疗8周、治疗12周、停药后4周,两组中医证候积分较本组治疗前基线下降率差异有统计学意义(P0.05)。治疗4周、治疗8周、治疗12周、停药后4周组间比较,中医证候积分及较基线下降率差异均无统计学意义(P0.05)。③治疗12周组间比较,ARCO分期差异无统计学意义(P0.05)。④两组安全性评价差异无统计学意义(P0.05)。结论通络生骨胶囊治疗股骨头坏死(筋脉瘀滞证)疗效满意,与健骨生丸相比,能更好地改善患者的髋关节功能功能,且安全可靠。     

Acellular dermal matrix reduces capsule formation in two‐stage breast reconstruction

Acellular dermal matrix (ADM) is commonly employed to create an inferior pocket for the tissue expander in two‐stage breast reconstruction. The authors sought to determine whether placement of ADM during the first stage of reconstruction decreases the amount of capsule formation at implant exchange. Patients who underwent mastectomy and tissue expander reconstruction were included in this study. Two biopsies were obtained at the time of implant exchange, one from the pocket adjacent to the ADM and the other from the area adjacent to the pectoralis muscle. Pathology analysis was performed on each sample. Ten patients underwent immediate breast reconstruction with Alloderm during the 3‐month study period. Capsule thickness was significantly greater in the areas where the expander was in direct contact with the pectoralis muscle (782 ± 194 µm) compared to those in contact with human acellular dermal matrix (hADM) (47·91 ± 110·82 µm; P < 0·05). Analysis of the sub‐pectoral capsule demonstrated diffuse deposition of collagen, neutrophils, contractile myofibroblasts and synovia‐like metaplasia, characteristic of a foreign body response. Conversely, within the inferior pocket where the hADM was in direct contact with the expander, we noted migration of host epithelial cells, fibroblasts, mesenchymal cells and angiogenesis, indicating host tissue regeneration. Acellular dermal matrix, when placed at the first stage of breast reconstruction, significantly reduces thickness and inflammatory character of the capsule in comparison to the patient's native tissue.